Shots:
- Galvanize Therapeutics has enrolled the first patient in the PROPEL registry trial evaluating the Aliya Pulsed Electric Field ablation system for soft tissue lesions, including primary and metastatic lung, liver, & other organ tumors
- Trial will evaluate clinical application, safety, perioperative outcomes, & radiographic response of the Aliya PEF system in ~1000 pts over 24mos. across 50 US centres
- Aliya PEF delivers short, high-voltage pulses either percutaneously or endoscopically to induce cell death while preserving surrounding tissues & structures to allow ablation in complex or previously irradiated regions. Preclinical & early clinical data also depicted potential trigger of antigen release & immune activation
Ref: PRNewsWire | Image: Galvanize| Press Release
Related News:- Myra Vision Receives FDA Conditional IDE Approval for Calibreye TGT System to Treat Glaucoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
